TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8633829
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with slow‐acting antirheumatic drugs (SAARDs)
Study: 8633829
Drug: Delayed introduction
Normalized name: INTRODUCTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed introduction of treatment with slow‐acting antirheumatic drugs (SAARDs)
Study: 1361594
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled beclomethasone dipropionate (BDP) 1500 micrograms/day
Study: 1361594
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled beclomethasone dipropionate (BDP) 300 micrograms/day
Study: 1361594
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose BDP
Study: 25135805
Drug: Community pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacist intervention discussing patients' beliefs about their medicines
Study: 12584832
Drug: Yiqi Wenyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Wenyang Huoxue Lishui (YWHL) treatment
Study: 7939438
Drug: Alarm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm treatment
Study: 28002202
Drug: HFM +
Normalized name: Hydroxyfasudil
DrugBank: Hydroxyfasudil (DB04707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFM + BH4 (5 mg/kg)
Study: 22086747
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761® (240 mg once daily)
Study: 19706018
Drug: Dorzolamide/timolol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol combination (DT)
Study: 1600965
Drug: Milrinone bolus
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone bolus dose (50 micrograms kg‐1) followed by infusion at rates of 0.375, 0.5 or 0.75 microgram kg‐1 min‐1
Study: 29209510
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion
Study: 6389233
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (CONT: 0.4 mU X kg‐1 X min‐1)
Study: 6389233
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin infusion (PULS: 0.8 mU X kg‐1 X min‐1, 7.5 min of 15)
Study: 27084832
Drug: Three weekly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weekly IMT sessions (high intensity) for five months
Study: 17366918
Drug: Preoperative amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative amino acid infusion
Study: 17366918
Drug: Perioperative amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative amino acid infusion
Study: 12002412
Drug: Octreotide (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (12 h infusion: bolus 0.75 microg/kg followed by 0.75 microg/kg/h)
Study: 9735391
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT group) with low-dose oral UFT and continuous venous 5FU infusion.
Study: 9735391
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (NCT group), n=28.
Study: 2109573
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (single 400‐mg dose)
Study: 2109573
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone (250‐mg dose)
Study: 31287556
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate with 200 mL mannitol
Study: 27621150
Drug: PF-05190457 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05190457 100 mg
Study: 27621150
Drug: PF-05190457 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05190457 150 mg
Study: 27621150
Drug: PF-05190457 ≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05190457 ≥50 mg
Study: 24481579
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg iv dexketoprofen trometamol
Study: 24481579
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg iv paracetamol
Study: 22162339
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) group program for RA fatigue
Study: 19074913
Drug: Prednisone 1-4
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1-4 mg/day
Study: 15893008
Drug: PORT (5040
Approvals — FDA: no, EMA: no, PMDA: no
Description: PORT (5040 cGy in 28 daily fractions)
Study: 15893008
Drug: CPORT (PORT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1‐3) administered concurrently)
Study: 15893008
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (PORT and CPORT)
Study: 12139537
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 30 ml with 30 mg ketamine (Group K)
Study: 12139537
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 30 ml (Group P)
Study: 12139537
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine with 30 mg ketamine i.v. (Group C)
Study: 7630678
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) at doses ranging from 0.125 to 4 mg/kg/day in two divided doses
Study: 7630678
Drug: Prior zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior zidovudine (ZDV) therapy
Study: 2756920
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A capsules
Study: 25968004
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (iCBT) program, completed over 10 weeks with six lessons.
Study: 23783784
Drug: PLBs under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PLBs under the guidance navigation system with a low-dose (LD) protocol
Study: 19318446
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral DHEA/day
Study: 17341993
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with valsartan and amlodipine
Study: 15194584
Drug: Ibuprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2400 mg/day)
Study: 15194584
Drug: Ibuprofen (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (in patients with knee swelling)
Study: 9395946
Drug: Ordinary oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary oxygen mask treatment (control group)
Study: 3481307
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide plus 600 mg mofebutazone
Study: 31098717
Drug: Neurogenic pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurogenic pain medication
Study: 29512813
Drug: Quadratus Lumborum
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadratus Lumborum Block type I with 24 mL 0.375% ropivacaine per side
Study: 18946293
Drug: Sugammadex (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (4.0 mg/kg)
Study: 7408650
Drug: Thyroxine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (50-150 micrograms daily)
Study: 31774566
Drug: F-652 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7
Study: 26062182
Drug: Acupuncture to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture to restore consciousness combined with hyperbaric oxygen treatment
Study: 26062182
Drug: Simple hyperbaric
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple hyperbaric oxygen treatment
Study: 21336131
Drug: alanine‐glutamine dipeptide‐supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: alanine‐glutamine dipeptide‐supplemented total parenteral nutrition
Study: 21336131
Drug: control total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: control total parenteral nutrition
Study: 17311603
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol laxative (17 g daily for 12 months)
Study: 7836506
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin, 500 micrograms/day s.c.)
Study: 26855561
Drug: Nemonoxacin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin with probenecid (1.5 g divided into three doses within 25 hours)
Study: 26855561
Drug: Nemonoxacin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin with cimetidine (400 mg thrice daily for 7 days)
Study: 18341671
Drug: ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 10 mg b.i.d. for 4.5 days
Study: 9773769
Drug: Mindfulness meditation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation-based stress reduction intervention (audiotaped instructions during light treatments)
Study: 9773769
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (light treatments alone with no taped instructions)
Study: 7522629
Drug: Chimeric anti-CD20
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) at doses of 10, 50, 100, 250, or 500 mg/m2
Study: 7522629
Drug: Chimeric anti-CD20
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8)
Study: 3122666
Drug: UFT 375
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 375 mg/m2/day + MMC 5 mg/m2 for 1‐2 weeks
Study: 3122666
Drug: UFT +
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT + ACNU 60 mg/m2/week for 2 weeks (with a 4-week interval)
Study: 24570980
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 mm dental implants with a novel nanostructured calcium-incorporated titanium surface
Study: 24570980
Drug: at least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least 10 mm long implants in augmented bone
Study: 24570980
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 mm dental implants
Study: 24570980
Drug: at least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least 10 mm long implants
Study: 16940217
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg, 3 times daily for 16 days
Study: 9106924
Drug: Ialugen cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ialugen cream (hyaluronic acid)
Study: 3705659
Drug: Telenzepine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 1 mg
Study: 3653758
Drug: Telenzepine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 2 mg
Study: 3653758
Drug: Telenzepine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 3 mg
Study: 3653758
Drug: Telenzepine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 5 mg
Study: 3705659
Drug: Telenzepine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (all doses)
Study: 26620496
Drug: MK-5108 monotherapy
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5108 monotherapy (Panel1) at doses ranging from 200 to 1800 mg, administered p.o. BID Q12h on days 1-2 in 14-21 day cycles.
Study: 26620496
Drug: MK-5108 in
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5108 in combination with docetaxel (Panel2) at 450 mg/day, administered IV docetaxel 60 mg/m2.
Study: 22122738
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser therapy (10,600-nm FLT, 10 mJ/microbeam, 35-45% coverage) for three to five sessions
Study: 22122738
Drug: Nonablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative fractional laser therapy (1,550-nm FLT, 15 mJ/microbeam, 14-20% coverage) for three to five sessions
Study: 22122738
Drug: Topical bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bleaching
Study: 19853332
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glutamate
Study: 3898832
Drug: Sucralfate (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (900 mg before meals and at bedtime)
Study: 31574879
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) applied for the treatment of infected dentin, followed by restoration with high viscosity glass ionomer cement.
Study: 28005265
Drug: tabalumab 100
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tabalumab 100 mg
Study: 28005265
Drug: tabalumab 300
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tabalumab 300 mg
Study: 24814500
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of LPS (0.8 ng/kg)
Study: 24814500
Drug: Low-dose LPS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LPS (0.4 ng/kg)
Study: 17582069
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (0.625 mg per day)
Study: 17582069
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (with at least 80% adherence)
Study: 10735926
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Study: 10735926
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Study: 9177359
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg testosterone cypionate biweekly for 12 months)
Study: 1539524
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of warfarin (within 48 hours of heparin)
Study: 1539524
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of warfarin (96 hours or later after heparin)
Study: 24326799
Drug: Intravenous Ergometrine
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ergometrine
Study: 23584366
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone (MR-pred) 5 mg/day
Study: 10979160
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment tailored to individual symptoms and standardized component for health and immune function
Study: 8971289
Drug: fedotozine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: fedotozine (30 mg t.d.s.)
Study: 1593505
Drug: Cognitive-behavioural problem
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural problem solving treatment
Study: 30426300
Drug: ATP (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP (160 mcg/kg/min)
Study: 30426300
Drug: Adenosine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (140 mcg/kg/min)
Study: 21071171
Drug: Standard occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard occupational therapy (SOT)
Study: 19898595
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Study: 19898595
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Study: 17767050
Drug: Lymphoplasmapheresis (LPE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoplasmapheresis (LPE) in addition to medical treatment
Study: 12101789
Drug: Metoprolol (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (initial dose of 15 mg intravenously, followed by 100 mg/d orally)
Study: 12101789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no metoprolol administered)
Study: 11225795
Drug: cHUT drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: cHUT drug-free phase
Study: 2080948
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of co-dergocrine mesilate and nifedipine (Pontuc)
Study: 469515
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of L‐tryptophan
Study: 469515
Drug: 1/4 g
Normalized name: THYROID 15-16MG (1/4 GR) CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/4 g of L‐tryptophan
Study: 469515
Drug: 1/2 g
Normalized name: Thyroid 1/2 Grain (30mg) Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 g of L‐tryptophan
Study: 30791804
Drug: sifalimumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifalimumab (IV 1.0, 3.0, and 10.0 mg/kg or subcutaneous 100 mg every 2 weeks; IV 600 and 1200 mg every 6 weeks)
Study: 30791804
Drug: sifalimumab (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifalimumab (same doses as Stage I or 600 mg IV every 4 weeks if enrolled later)
Study: 28137336
Drug: 8-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week group Cognitive Behavioural Therapy for perfectionism (CBT-P)
Study: 19395071
Drug: Postoperative morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative morphine-bupivacaine PCEA
Study: 19395071
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous morphine PCA
Study: 9284850
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of sertraline (after a single dose of desipramine)
Study: 9284850
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of sertraline (after multiple doses of desipramine)
Study: 9284850
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of sertraline (after a single dose of imipramine)
Study: 9284850
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of sertraline (after multiple doses of imipramine)
Study: 8511496
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine twice daily (group 1)
Study: 8511496
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine twice daily (group 2)
Study: 8511496
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine twice daily (group 3)
Study: 29113986
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg MPX (low dose)
Study: 29113986
Drug: 4,000 mg
Normalized name: lysine acetate 4,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 mg MPX (high dose)
Study: 29113986
Drug: MPX (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPX (pooled treatment arms) in SOD2 Alanine/Alanine genotype patients
Study: 27827328
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment in high CBS group
Study: 24726142
Drug: Neoadjuvant sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sorafenib treatment for 4 weeks before tumor nephrectomy
Study: 20614124
Drug: Telmisartan 40/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40/80 mg once daily
Study: 20206670
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months
Study: 12094857
Drug: Balsalazide (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide (2.25 g daily)
Study: 12094857
Drug: Mesalamine (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (2.4 g daily)
Study: 10379633
Drug: moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 15 mg once daily
Study: 10379633
Drug: nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 20 mg once daily
Study: 9289465
Drug: Phenazone (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazone (18 mg/kg body mass) administered orally after surgical ovariectomy
Study: 9289465
Drug: Phenazone (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazone (18 mg/kg body mass) administered orally before surgical ovariectomy
Study: 6499895
Drug: Clonidine (CLON)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (CLON) 0.2 mg daily
Study: 6499895
Drug: Moxonidine (MOX)
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (MOX) 0.2 mg daily
Study: 16116971
Drug: CPA +
Normalized name: Cyproterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA + metformin (n = 25)